Article

KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development

2023-07-03

Abstract excerpt

<h4>ABSTRACT</h4> Oncogenic mutations in KRAS are present in approximately 95% of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) and are considered the initiating event of pancreatic intraepithelial neoplasia (PanIN) precursor lesions. While it is well established that KRAS mutations drive the activation of oncogenic kinase cascades during pancreatic oncogenesis, the effects of oncogenic KRAS sig...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d37430d3-3a94-5702-ac14-afefa1ea0715
DOI: 10.1101/2023.07.01.547283

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer developmentDOI 10.1101/2023.07.01.547283Read

Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDACSemantic proximity Read

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of TherapySemantic proximity Read

KRAS-dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS InhibitorsSemantic proximity Read

Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy.Semantic proximity Read

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progressionSemantic proximity Read

Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.Semantic proximity Read

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.Semantic proximity Read

Oncogenic KRAS signalling in pancreatic cancerSemantic proximity Read

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition.Semantic proximity Read

Kras as a key oncogene and therapeutic target in pancreatic cancerSemantic proximity Read

Mutant KRAS in the initiation of pancreatic cancer.Semantic proximity Read